CCL2 and type 2 diabetes mellitus: Since serum levels of MCP-1 are elevated in patients with type 2 diabetes [6], as are levels of TNF-α and interleukin-6 [7], it is conceivable that diabetics mount an exaggerated immune response to C. neoformans (paradoxical to their defective immune state) leading to fatal outcomes.